PHP16 OUTHOSPITAL DRUG CONSUMPTION IN MONTENEGRO IN 2007  by Tomic, Z et al.
Greece. The study was carried out in 2006 and participants were
face-to-face interviewed to report on their use of pharmaceuticals
and on the number of pharmaceuticals taken in a speciﬁed recent
period. Multivariable logistic regression analysis was performed
to ascertain the predictive factors of the pharmaceutical con-
sumption. Statistical signiﬁcance was accepted at the 5% level.
RESULTS: A total of 43.7% of the sample had used pharmaceu-
ticals. Age, chronic diseases, HRQoL, number of physician
consultations and hospitalization were best predictors of phar-
maceutical use. Factors associated with higher likelihood of using
pharmaceuticals were elderly people (exp(b) = 1.72, CI:1.51–
1.70), chronic diseases (exp(b) = 6.61, CI:3.39–9.96), poorer
HRQOL (PSC12 exp(b) = 0.93, CI:0.90–0.95, MCS12
exp(b) = 0.97, CI:0.93–0.99) and number of physician consulta-
tions during the last year (exp(b) = 3.05, CI:1.96–4.76). On the
other hand, taking four or more pharmaceuticals concurrently
were best predicted by older age (exp(b) = 1.52, CI:1.11–2.09),
chronic diseases (exp(b) = 3.84, CI: 1.58–5.94), poorer HRQOL
(PCS12 exp(b) = 0.95, CI:0.92–0.97, MCS12 exp(b) = 0.95, CI:
0.93–0.98), number of physician consultations during the year
(exp(b) = 3.59, CI: 1.36–5.41) and hospitalization during the last
year (exp(b) = 2.13, CI:1.13–4.02). CONCLUSIONS: Pharma-
ceutical use is related to population aging (combined with
chronic disease) a fact that should be a cause of concern in the
future, taking into account the demographic problem in the
western societies.
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OBJECTIVES: The aim of this research was to analyze outhospi-
tal drug consumption in Montenegro in 2007, and to compare
data with drug consumption in previous period. The aim was also
to compare drug consumption in Montenegro with drug con-
sumption in countries with developed prarmacotherapeutic prac-
tice. METHODS: Drug consumption was analyzed by number of
DDD per 1000 inhabitants per day. Consumption of ﬁnancial
resources was analyzed as well. RESULTS: Total outhospital drug
consumption funded by Republic Health Fund of Montenegro in
2007. was 278.59 DDD/1000 inhabit./day. The highest consump-
tion was in group C (drugs for cardiovascular diseases) with
149.29 DDD/1000 inhabit./day (53.59% of total drug consump-
tion). Second highest consumption was in group A (drugs for
alimentary tract andmetabolism)with 34.67 DDD/1000 inhabit./
day (12.45% of total drug consumption). Drugs for nervous
system participated with 10.50% in total drug consumption with
29.25 DDD/1000 inhabit./day. Total drug consumption funded
by Republic Health Fund of Montenegro in 2007. was increased
for 36.68% compared to drug consumption in 2005.
(203.82 DDD/1000 inhabit./day). Increase in drug consumption
resulted in increased consumption of ﬁnancial resources
(12.859.961.58 €) which were higher for 2.857.855.73 € then in
2005. Highest increase in consumption of ﬁnancial resources was
in group C (€1,096.468.28 in 2007.), group A (€559,827.80
in 2007.), group R (€468,156.55 in 2007.) and group N
(€452,212.30 in 2007.). CONCLUSIONS: Although there was a
signiﬁcant decrease in drug consumption in Montenegro in 2007.
compared to 2005. drug consumption in 2007. was much lower
then in Scandinavian countries. Detailed analysis in separate ATC
groups of drugs reveal that consumption is not always rational
from pharmacoterapeutic and pharmacoeconomic point of view.
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OBJECTIVES: To identify most frequently used and most inﬂu-
ential sources of information on drugs in Poland, as well as to
determine their credibility as perceived by GPs’ and possible
factors limiting access to these sources. METHODS: An anony-
mous survey was conducted among one hundred GPs in ambu-
latories in Warsaw, Poland. GPs were questioned about the
sources of information used in the past six months and frequency
of usage. GPs were also asked to divide 100 pts to indicate the
most important limitations in access to sources, the perceived
credibility of the sources and the sources inﬂuencing the decision
most. Demographic questions were included. RESULTS:
[UNKNOWN NODETYPE 9] Only 25% GPs considered them-
selves limited in the access to drug information, while 69%
believed the information was sufﬁcient. The most frequent bar-
riers referred to GPs themselves: lack of foreign language skills
(average of 24.7 points); money limitations (22.4), lack of time
(20.87 pts), no EBM competency (20.6). There is a statistically
signiﬁcant (all tests for a = 0.05) negative relation between usage
and perceived limitations. Younger GPs perceived lack of infor-
mation statistically signiﬁcantly more often (Fisher’s exact test).
The sources that were most frequently used in the past 6 months
were: drug directories (96% GPs), pharmaceutical companies
representatives (93%), polish professional journals (92.6%).
High importance of commercial sources conﬁrmed previous
results of POLKARD-SPOK survey in Poland and agrees with
results of surveys in other countries. On the other hand the SPOK
survey showed higher role of Polish professional journals. GPs
declared that drug selection is inﬂuenced most by medical jour-
nals (29.16 pts), medical books (24.93), and information from
pharmaceutical companies representatives (21.15). There is a
slight discrepancy between usage and inﬂuence, which may
suggest an element of wishful thinking. CONCLUSIONS: Rela-
tively few GPs feel insufﬁciently informed. Whether this is an
objective (i.e. results from their proﬁciency) or subjective fact (i.e.
results from their lack of knowledge of information gap) should
be a matter of further studies. Information gained from pharma-
ceutical companies representatives is an important factor both in
terms of frequency and impact on decisions. Confronting this
with limitations of GPs in gathering new information by them-
selves proves there is a need for EBM popularization in Poland.
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OBJECTIVE: In the last years, economic evaluations with
quality adjusted life year (QALY) as effectiveness variable
increased. Cost-utility analyses are generally preferred by health
care policy makers and payers, because include both quality and
quantity of life. Also, QALY allows comparing different inter-
ventions with the same evaluation unit. The majority of eco-
nomic studies evaluate drugs, despite of increment of diagnostic
and therapeutic devices studies in the last years. The main objec-
tive consists on a comparison of Cost/QALY ratio in diagnostic
and therapeutic devices with drug treatments in studies devel-
oped in the Spanish setting in the last 12 years. METHOD: A
Spanish cost-effectiveness and cost-utility studies review was
developed, including all published studies during the last 12
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